Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasm Metastasis × nintedanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Recurrence 3 Ovarian Neoplasms 3 Colorectal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Radiation Pneumonitis 2 Prostatic Neoplasms 2 Mesothelioma, Malignant 2 Lung Neoplasms 2 Glioblastoma 2 Fallopian Tube Neoplasms 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Ovarian Diseases 1 Oligodendroglioma 1 Neoplasms by Site 1 Neoplasms 1 Neoplasm Metastasis 1 Leukemia, Myeloid, Acute 1 Inflammatory Breast Neoplasms 1 Head and Neck Neoplasms 1 Gliosarcoma 1 Esophagogastric Adenocarcinoma 1 Endometrial Neoplasms 1 Endometrial Adenocarcinoma 1 Carcinoma, Transitional Cell 1

Interventions

Oxaliplatin 56 Capecitabine 54 Fluorouracil 51 Bevacizumab 49 Gemcitabine 44 Leucovorin 43 Paclitaxel 41 Carboplatin 35 Nivolumab 33 Irinotecan 32 pembrolizumab 31 Docetaxel 31 Cetuximab 30 Cisplatin 29 Trastuzumab 21 Radiosurgery 20 Sunitinib 19 Cyclophosphamide 19 Panitumumab 18 Doxorubicin 17 Radiotherapy 15 Pemetrexed 15 Fulvestrant 15 Drug Therapy 15 Interleukin-2 14 Everolimus 14 atezolizumab 13 Sorafenib 13 Ipilimumab 13 Biopsy 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02856867 2017-05-09

MEGAN

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡